Dr. Simon Khagi, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 89
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license 187017 · NH license 15414
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- Hoag Memorial Hospital Presbyterian Newport Beach, CA
Medical groups
- Hoag Clinic (460 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 89
- Services billed
- 1,118
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 306 | 107 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 19 | 17 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fluoxetine Hcl Other prescribers in Newport Beach, CA | 108 |
| Ondansetron Odt (ondansetron) Other prescribers in Newport Beach, CA | 47 |
| Tagrisso (osimertinib mesylate) | 46 |
| Levetiracetam Other prescribers in Newport Beach, CA | 38 |
| Olanzapine Other prescribers in Newport Beach, CA | 36 |
| Dexamethasone Other prescribers in Newport Beach, CA | 32 |
| Pantoprazole Sodium Other prescribers in Newport Beach, CA | 23 |
| Levothyroxine Sodium Other prescribers in Newport Beach, CA | 22 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Newport Beach, CA | 22 |
| Ondansetron Hcl Other prescribers in Newport Beach, CA | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 46 payments worth $38,756 in total to this clinician.
| Novocure Inc. | $37,752 |
|---|---|
| Galvanize Therapeutics, Inc | $620 |
| Servier Pharmaceuticals LLC | $128 |
| Insightec,inc | $95.28 |
| Array Biopharma Inc | $59.29 |
| Telix Pharmaceuticals | $39.74 |
| Amgen Inc. | $32.72 |
| Jazz Pharmaceuticals Inc. | $29.39 |
| Speaking at a medical education program | $17,225 |
|---|---|
| Honoraria | $9,890 |
| Consulting Fee | $7,550 |
| Travel and Lodging | $2,839 |
| Food and Beverage | $1,184 |
| Education | $68.67 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novocure Inc. Jul 3, 2025 | Consulting Fee | $4,550 |
| Novocure Inc. Jun 20, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $4,225 |
| Novocure Inc. May 7, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $4,225 |
| Novocure Inc. Dec 4, 2025 | Honoraria Optune Lua (NovoTTF-200T) · Oncology | $3,575 |
| Novocure Inc. May 23, 2025 | Honoraria Optune Lua (NovoTTF-200T) · Oncology | $2,740 |
| Novocure Inc. Jun 12, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $1,950 |
| Novocure Inc. Dec 10, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $1,950 |
| Novocure Inc. Sep 11, 2025 | Consulting Fee Optune Lua (NovoTTF-200T) · Oncology | $1,950 |
| Novocure Inc. Nov 5, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $1,950 |
| Novocure Inc. Jan 30, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $1,950 |
All 28 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novocure Inc. Dec 10, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $1,950 |
| Novocure Inc. Dec 4, 2025 | Honoraria Optune Lua (NovoTTF-200T) · Oncology | $3,575 |
| Novocure Inc. Dec 4, 2025 | Honoraria Optune Lua (NovoTTF-200T) · Oncology | $1,950 |
| Novocure Inc. Dec 4, 2025 | Travel and Lodging Optune Lua (NovoTTF-200T) · Oncology · travel to San Francisco, CA | $74.16 |
| Novocure Inc. Nov 5, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $1,950 |
| Novocure Inc. Oct 30, 2025 | Consulting Fee Optune Lua (NovoTTF-200T) · Oncology | $650 |
| Novocure Inc. Oct 28, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $325 |
| Novocure Inc. Sep 28, 2025 | Travel and Lodging Optune Gio · Oncology · travel to San Francisco, CA | $448 |
| Novocure Inc. Sep 12, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $650 |
| Novocure Inc. Sep 11, 2025 | Consulting Fee Optune Lua (NovoTTF-200T) · Oncology | $1,950 |
| Novocure Inc. Aug 21, 2025 | Travel and Lodging Optune Gio · Oncology · travel to san francisco, CA | $282 |
| Novocure Inc. Aug 21, 2025 | Travel and Lodging Optune Gio · Oncology · travel to san francisco, CA | $3.00 |
| Novocure Inc. Jul 23, 2025 | Honoraria Optune Lua (NovoTTF-200T) · Oncology | $1,625 |
| Amgen Inc. Jul 16, 2025 | Education in-kind | $32.72 |
| Novocure Inc. Jul 3, 2025 | Consulting Fee | $4,550 |
| Novocure Inc. Jun 20, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $4,225 |
| Novocure Inc. Jun 20, 2025 | Travel and Lodging Optune Lua (NovoTTF-200T) · Oncology · travel to Fresno, CA | $473 |
| Novocure Inc. Jun 20, 2025 | Travel and Lodging Optune Lua (NovoTTF-200T) · Oncology · travel to Fresno, CA | $363 |
| Novocure Inc. Jun 20, 2025 | Travel and Lodging Optune Lua (NovoTTF-200T) · Oncology · travel to Fresno, CA | $233 |
| Novocure Inc. Jun 12, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $1,950 |
| Novocure Inc. May 23, 2025 | Honoraria Optune Lua (NovoTTF-200T) · Oncology | $2,740 |
| Novocure Inc. May 7, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $4,225 |
| Novocure Inc. May 7, 2025 | Travel and Lodging Optune Lua (NovoTTF-200T) · Oncology · travel to Phoenix, AZ | $522 |
| Novocure Inc. May 7, 2025 | Travel and Lodging Optune Lua (NovoTTF-200T) · Oncology · travel to Phoenix, AZ | $262 |
| Novocure Inc. May 7, 2025 | Travel and Lodging Optune Lua (NovoTTF-200T) · Oncology · travel to Phoenix, AZ | $179 |
| Novocure Inc. May 3, 2025 | Education Optune Lua (NovoTTF-200T) · Oncology | $35.95 |
| Novocure Inc. Jan 30, 2025 | Speaking at a medical education program Optune Lua (NovoTTF-200T) · Oncology | $1,950 |
| Galvanize Therapeutics, Inc Jan 29, 2025 | Consulting Fee ALIYA SYSTEM · PULSED ELECTRIC FIELD | $400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $176,486 in research payments for these studies, mostly to the institutions running them.
- A pivotal study to evaluate the safety and effectiveness of Exablate Model 4000 using Micorbubble Resonators to Temporarily Mediate Blood Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with Glioblastoma…
Insightec,ltd - EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma
Novocure GmbH - EF-44 Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.